HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Troy’s odyssey

This article was originally published in The Tan Sheet

Executive Summary

Former FDA Chief Counsel Dan Troy and Special Assistant to the Chief Counsel Coleen Klasmeier will join Sidley Austin Brown & Wood this month, the law firm announces Jan. 6. Troy will provide "strategic counsel on FDA-related matters" and practice administrative and constitutional law with a focus on the pharma, biotech and medical device industries; he announced his departure from FDA in November (1"The Tan Sheet" Nov. 22, 2004, p. 10). Klasmeier is joining the firm's life sciences practice with a focus on the pharma, medical device and food industries...

You may also be interested in...



FDA Chief Counsel Warning Letter Review To Continue After Troy’s Departure

The FDA Office of Chief Counsel's review of warning and untitled letters has resulted in the rejection of approximately 5% of letters, outgoing Chief Counsel Daniel Troy said

Alleged ‘Pink Tax’ Class Actions Against OTC Personal-Care Brands Moving Through Federal Courts

Walgreen Co. seeks to dismiss allegations in California’s Northern District that it unlawfully charges more for its OTC Hair Regrowth Treatment for women compared with a “functionally equivalent” offering for men. The suit follows “pink tax” litigation concerning Dove antiperspirants that defendants dismissed in July 2020, a decision affirmed by the Eighth Circuit in May.

Lumakras A Big Focus For Amgen; More Data Coming Soon

Amgen reported 5% year-over-year revenue growth to $6.5bn in the second quarter, up 11% from Q1. It did not break out Lumakras sales but detailed upcoming data that may support future indications.

Topics

UsernamePublicRestriction

Register

RS126774

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel